In the metastatic setting, HER2 molecular imaging using 89Zirconium-labeled trastuzumab is being tested as a noninvasive whole-body imaging technique to determine tumour HER2 expression status and the localisation of tumour lesions HER2-positive, especially those inaccessible to biopsy [38], The IJBMNZrT003 trial (NCT01420146) is a phase I trial testing this diagnostic potential of HER2-positive tumours using 89Zirconium-labeled trastuzumab. The gene discussed is ERBB2; the disease is neoplasm.